Crown Bioscience, a JSR Life Sciences company, earns Fierce CRO Award for global operations excellence in oncology and immuno-oncology drug development services.
Read articleCrown Bioscience achieves 'Green' My Green Lab Certification in the Netherlands, highlighting leadership in sustainable lab best practices worldwide.
Crown Bioscience and NEXT Oncology renew collaboration, combining global clinical trial expertise and innovative cancer models for oncology drug development.
Crown Bioscience launches 3D bone marrow niche in vitro models at AACR 2025, advancing predictive oncology screening for hematological malignancies.
KBI Biopharma, a JSR Life Sciences company, wins global recognition for excellence in biologics manufacturing at the 2025 CDMO Leadership Awards.
Crown Bioscience appoints John Gu as CEO, leveraging his expertise in AI-driven drug discovery to advance biotechnological innovation and global health.
Crown Bioscience completes Indivumed Services merger, offering enhanced drug development solutions globally and retiring the Indivumed brand.
Crown Bioscience's Hamburg site secures continued CAP ISO 15189:2022 accreditation, showcasing its commitment to quality in laboratory services.
Crown Bioscience wins 2024 Fierce CRO Award for excellence in client service, underscoring its commitment to innovative drug development partnerships.
Crown Bioscience's OrganoidXplore receives BioTech Award, revolutionizing oncology with advanced preclinical screening.
KBI Biopharma Selected as CDMO of Choice to Fast-Track Development of Pre-Clinical Antibody for Blood Cancers Using SUREmAbTM Technology
Crown Bioscience, part of JSR Life Sciences, joins a €1.75M Eurostars project to develop a novel liquid biopsy for prostate cancer, enhancing treatment.
Crown Bioscience enhances its global presence with the expansion of its Singapore facility, featuring cutting-edge oncology models and imaging capabilities.
Crown Bioscience, a JSR Life Sciences company, earns Fierce CRO Award for global operations excellence in oncology and immuno-oncology drug development services.
Crown Bioscience achieves 'Green' My Green Lab Certification in the Netherlands, highlighting leadership in sustainable lab best practices worldwide.
Crown Bioscience and NEXT Oncology renew collaboration, combining global clinical trial expertise and innovative cancer models for oncology drug development.
Crown Bioscience launches 3D bone marrow niche in vitro models at AACR 2025, advancing predictive oncology screening for hematological malignancies.
KBI Biopharma, a JSR Life Sciences company, wins global recognition for excellence in biologics manufacturing at the 2025 CDMO Leadership Awards.
Crown Bioscience appoints John Gu as CEO, leveraging his expertise in AI-driven drug discovery to advance biotechnological innovation and global health.
Crown Bioscience completes Indivumed Services merger, offering enhanced drug development solutions globally and retiring the Indivumed brand.
Crown Bioscience's Hamburg site secures continued CAP ISO 15189:2022 accreditation, showcasing its commitment to quality in laboratory services.
Crown Bioscience wins 2024 Fierce CRO Award for excellence in client service, underscoring its commitment to innovative drug development partnerships.
Crown Bioscience's OrganoidXplore receives BioTech Award, revolutionizing oncology with advanced preclinical screening.
KBI Biopharma Selected as CDMO of Choice to Fast-Track Development of Pre-Clinical Antibody for Blood Cancers Using SUREmAbTM Technology
Crown Bioscience, part of JSR Life Sciences, joins a €1.75M Eurostars project to develop a novel liquid biopsy for prostate cancer, enhancing treatment.
Crown Bioscience, a JSR Life Sciences company, earns Fierce CRO Award for global operations excellence in oncology and immuno-oncology drug development services.
Crown Bioscience achieves 'Green' My Green Lab Certification in the Netherlands, highlighting leadership in sustainable lab best practices worldwide.
Crown Bioscience and NEXT Oncology renew collaboration, combining global clinical trial expertise and innovative cancer models for oncology drug development.
Crown Bioscience launches 3D bone marrow niche in vitro models at AACR 2025, advancing predictive oncology screening for hematological malignancies.
Crown Bioscience appoints John Gu as CEO, leveraging his expertise in AI-driven drug discovery to advance biotechnological innovation and global health.
Crown Bioscience completes Indivumed Services merger, offering enhanced drug development solutions globally and retiring the Indivumed brand.
Crown Bioscience's Hamburg site secures continued CAP ISO 15189:2022 accreditation, showcasing its commitment to quality in laboratory services.
Crown Bioscience wins 2024 Fierce CRO Award for excellence in client service, underscoring its commitment to innovative drug development partnerships.
Crown Bioscience's OrganoidXplore receives BioTech Award, revolutionizing oncology with advanced preclinical screening.
Crown Bioscience, part of JSR Life Sciences, joins a €1.75M Eurostars project to develop a novel liquid biopsy for prostate cancer, enhancing treatment.
Crown Bioscience enhances its global presence with the expansion of its Singapore facility, featuring cutting-edge oncology models and imaging capabilities.
Crown Bioscience announces a strategic partnership with Clinical Trial & Consulting Services (CTI), a renowned global full-spectrum research service provider, to bolster oncology-focused consulting...
KBI Biopharma, a JSR Life Sciences company, wins global recognition for excellence in biologics manufacturing at the 2025 CDMO Leadership Awards.
KBI Biopharma Selected as CDMO of Choice to Fast-Track Development of Pre-Clinical Antibody for Blood Cancers Using SUREmAbTM Technology
Extension reinforces KBI’s commitment to forge long-term partnerships to successfully address complex clinical development and commercialization challenges.
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Peter Carbone as the new Chief Quality...
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Argonaut Manufacturing Services, Inc. (Argonaut), a cGMP contract man...
KBI Biopharma, Inc. (KBI Biopharma), a JSR Life Sciences company, today announced the launch of SUREmAb™, an offering built on the robustness of KBI’s SUREtechnology Platform, that allows for optim...
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced four recent executive appointments to continue its momentum and vision of becoming a next-generation CDMO.
Platform leverages proprietary PUREcoli™ strain and cutting-edge screening packages for unmatched efficiencies and optimized production processes
KBI’s new model will enhance operational efficiencies, drive strategic clarity, and accelerate innovation for global biopharma customers
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced the appointment of Marykay Marchigiani as Chief Financial Officer and Sigma Mostafa, Ph.D., as Chief Scientific Officer. The ...
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced the appointment of David Stewart as the new SVP and Site Head of KBI’s mammalian cGMP manufacturing facility in Durham, North...
Milestone affirms KBI and Selexis SA’s Geneva cGMP site is operational and running successfully
Amsphere™ A+ enhances antibody drug production with advanced polymer technology and high binding capacity, debuting at BPI 2024 and BioJapan.
JSR-AIF participated in the Series D financing of Aillis for the purpose of raising funds to accelerate research and development of AI medical devices, sales, and marketing promotion
Through joint development with Bacchus Bio innovation, JSR will develop and produce raw materials for its key biomass products utilizing synthetic biology.
Ajinomoto Co. has reached an agreement with JSR to collaborate on the global expansion of its biopharmaceutical culture media business, adding new high-performance media developed by JSR, to Ajinom...
JSR Corporation announced today that it has entered into a facility usage agreement with AuB, a company engaged in the study of intestinal microbiota in athletes.
JSR Corporation announced today that it has concluded a facility use agreement with KINS Co., Ltd. (KINS), a company with a database of human microbiome.
JSR Life Sciences, LLC is pleased to announce that JSR Corporation and Asahi Kasei Medical have entered into a co-promotion agreement for bioprocess products and materials that initiated sales coll...
JSR Life Sciences is committed to the advancement of human health worldwide as a strategic partner to companies that discover, develop & deliver products to treat disease & improve quality of life
Crown Bioscience is a contract research & translational technology company making precision medicine a reality
KBI Biopharma is an award winning CDMO providing fully-integrated, accelerated drug development & biomanufacturing services to pharmaceutical & biotechnology companies globally
JSR Corporation's mission is to contribute to social good by supplying materials to serve future generations & providing new value today for their customers & society
Are you a journalist or do you work for a publication?
Sign up and request access to exclusive news.
Find news releases, media kits and clippings
